Navigation Links
NutraCea Announces First Quarter 2008 Financial Results
Date:5/12/2008

PHOENIX, May 12 /PRNewswire-FirstCall/ -- NutraCea (OTC Bulletin Board: NTRZ), a world leader in stabilized rice bran (SRB), nutrient research and technology, today announced financial results for its first quarter ended March 31, 2008. Consolidated net revenues rose 155% to $5.1 million for the first quarter of 2008, compared to consolidated net revenues of $2.0 million for the first quarter of 2007. The $3.1 million increase was primarily due to a $860,000 increase in sales of products produced in the United States, an increase of $17,000 in royalty revenues and $2.2 million in sales from the Company's Irgovel subsidiary in Brazil for the period February 19, 2008 through March 31, 2008.

The Company reported a net loss of $(6.8) million, or $(0.05) per share, compared to a net loss of $(247,000), or $0.00 per share for first quarter 2007. The loss was primarily due to a $4.5 million increase in operating expenses and a net decrease in Other Income and Expenses (net) of $1.4 million.

Sales, General and Administrative (SG&A) expenses were $5.2 million, compared to SG&A of $2.3 million for the first quarter of 2007. This increase was primarily due to expanded investment in personnel, infrastructure and sales and marketing activities to meet anticipated future demands. In the quarter we wrote down $390,000 in connection with a doubtful note receivable. The Company's professional fees were $2.0 million compared to $459,000 for the same quarter last year. These expenses were primarily due to consulting and legal fees of approximately $621,000 in connection with marketing and business development, SOX 404 activities, the acquisition of Irgovel and our investment in PT Panganmas Inti Nusantara, an Indonesian Company (PIN), made through our Medan LLC subsidiary. We also incurred a $750,000 broker fee which included the estimated value of an option to be issued related to our investment PIN. Of the $5.2 million in SG&A during the quarter, approximately $
'/>"/>

SOURCE NutraCea
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. NutraCea Appoints Financial Relations Board as New Investor Relations Firm
2. NutraCea to Host Third Quarter 2007 Financial Results Conference Call November 14
3. NutraCea Announces Conference Call to Report Second Quarter Financial Results
4. NutraCea Forms Joint Ventures With HerbalScience to Develop Nutraceutical Extracts and Pharmaceutical Chemistries From Stabilized Rice Bran
5. NutraCea Provides Update on Domestic Operations
6. NutraCea Files Universal Shelf Registration Statement
7. NutraCea to Purchase Largest Rice Bran Oil Processing Facility in South America
8. New World Record Holder in Powerlifting Credits NutraCeas Unique Rice-Bran-derived Product as his Secret Weapon
9. NutraCea Appoints New Chief Financial Officer
10. NutraCea-Sponsored Study Demonstrates Benefits of Replacing Wheat Flour with Stabilized Rice Bran (SRB) in Battered and Fried Product Applications
11. Demand for NutraCea Rice Bran Oil Prompts Major Expansion of Irgovel Plant Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...lt University say that constant exposure to artifi...nt of premature babies' biological// clocks. The s...e researchers found that the lighting in the hospi...cal clock in the babies. Earlier research had fou...
...headache, you are probably better off eating a bow...ulatory doses of aspirin, according// to a new stu...nd that salicylic acid, the active ingredient in a...spices like cumin, turmeric and paprika, all of wh...
... Luther King Jr./Drew Medical Center explained, th...deavor to get back the accreditation along with// ... Antionette Smith Epps, chief executive of the hos...adership team that is determined to inculcate a se...
...o-school survey on teens' attitudes that covers an...ss about children’s immoral practices, one// third...here alcohol or illegal drugs were used while thei...ply that parents were aware of what was happening ...
Other Medicine News:Health News:Parents ignorant about kids' immoral practices 2
(Date:9/4/2008)...ouncements Remain on Schedule with Two Abstracts A...ata Release in November 2008, BRIDGEWATER, N.J., ...Inc., a specialty pharmaceutical company focused o...sease, today announced the appointment of,Peter L....rs., Peter Garrambone,s career includes more than...
(Date:9/3/2008)..., China, Sept. 3 /- Simcere...ufacturer and supplier of,branded generic pharmace...er biotech product Endu (also known as Endostar) i...se IV clinical study., At the request of the SFDA...urther validate the safety and therapeutic efficac...
(Date:9/3/2008)...September is National Vascular Disease Awareness M...-- Diffusion Pharmaceuticals,LLC, a clinical-stage...s,for the treatment of unmet medical needs, announ...a Phase I/II clinical trial of its lead drug,candi...signated NCT00725881,on the clinicaltrials.gov Web...
(Date:9/3/2008)...ysis showed that Multaq(R) (dronedarone) decreased...fibrillation or atrial flutter already ...RIDGEWATER, N.J., Sept. 3 /...rom the ATHENA study were presented today at,the c...ty of Cardiology,congress 2008, in Munich, Germany...
Breaking Medicine Technology:Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5The HealthCentral Network Adds Skin Care Site to Its Web Properties 7104 1The HealthCentral Network Adds Skin Care Site to Its Web Properties 7104 2NanoLogix Inc Files Multiple International Patent Applications for BioNanoChannel 28TM 29 and Hydrogen Bioreactor Technology 7100 1NanoLogix Inc Files Multiple International Patent Applications for BioNanoChannel 28TM 29 and Hydrogen Bioreactor Technology 7100 2MetaCure 28TM 29 Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight 7096 1MetaCure 28TM 29 Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight 7096 2Pneumococcal conjugate vaccines can improve the lives of HIV infected children 7092 1Pneumococcal conjugate vaccines can improve the lives of HIV infected children 7092 2
... March 27, 2007--A new study shows that as rates,o...of,cardiovascular disease (CVD) linked to diabetes...e need for increased efforts to,prevent diabetes a...ors among those with diabetes, according to the in...t Study, a program of the,National Heart, Lung, an...
...sults for the year ended 31 December 2006 , Produc...e Phase,III study International partnering process..., March 28, 2007 - CeNeS Pharmaceuticals,plc ("CeN...specialty pharmaceutical company, today announces ...mber 2006. , Operational Highlights , Clinical pip...
Other Medicine Technology:Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 2Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 3CeNeS Pharmaceuticals Plc Announces Preliminary Results for The,Year Ending 31 December 2006 2CeNeS Pharmaceuticals Plc Announces Preliminary Results for The,Year Ending 31 December 2006 3
Used as a percutaneous entry needle to introduce wire guides. The coaxial design reduces potential A.V. malformations. Supplied sterile in peel-open packages. Intended for one-time use.
Used for stone manipulation and removal in the urinary tract. Enhanced wire strength permits the basket to expand the ureter more readily than standard flat-wire designs. The Unidex handle facilitate
...d for stone manipulation and removal in the urinar... to retain its shape following extreme torsion. Th...ture by allowing the basket to open at the base of...ign reduces the likelihood of mucosal damage and p...
Used to establish and maintain nephrostomy drainage following pyeloplasty. Supplied sterile in peel-open packages. Intended for one-time use. CAUTION: Periodic evaluation is advised; stent must not r
Medicine Products: